Bank of America
CGON icon

Bank of America’s CG Oncology CGON Stock Holding History

Bank of America’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70M Sell
984,918
-464,446
-32% -$30.4M ﹤0.01% 1446
2026
Q1 		$98.1M Buy
1,449,364
+259,311
+22% +$14.7M 0.01% 1130
2025
Q4 		$49.4M Buy
1,190,053
+441,708
+59% +$18.3M ﹤0.01% 1573
2025
Q3 		$30.1M Sell
748,345
-988,424
-57% -$28.7M ﹤0.01% 2200
2025
Q2 		$45.2M Buy
1,736,769
+1,396,170
+410% +$33.6M ﹤0.01% 1793
2025
Q1 		$8.34M Buy
340,599
+131,081
+63% +$3.69M ﹤0.01% 3323
2024
Q4 		$6.01M Buy
209,518
+38,626
+23% +$1.32M ﹤0.01% 3410
2024
Q3 		$6.45M Buy
170,892
+114,697
+204% +$4.02M ﹤0.01% 3494
2024
Q2 		$1.77M Buy
56,195
+42,048
+297% +$1.46M ﹤0.01% 4527
2024
Q1 		$621K Buy
+14,147
New +$578K ﹤0.01% 5218

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's CGON Position: Q2 2026 in Review

Bank of America reduced its CG Oncology (CGON) stake by 32% in Q2 2026, selling an estimated $30.4M and leaving 984,918 shares worth $70M. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Bank of America first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $98.1M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Bank of America held 984,918 shares of CG Oncology worth $70M as of Q2 2026.
  • Bank of America sold 464,446 CG Oncology shares in Q2 2026, an estimated $30.4M.
  • CG Oncology made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1446 holding.
  • Bank of America first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • Bank of America's CG Oncology position peaked at $98.1M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.